- Organizations: Lenz Therapeutics
Products
FDA approves LENZ Therapeutics' VIZZ for presbyopia
LNZ100, now VIZZ, is the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults.
Pipeline
LENZ and Théa partner on Canadian commercialization of presbyopia eye drop
Licensing and commercialization agreement gives LENZ $70 million in upfront and milestone payments; news comes as company awaits FDA approval.
Pipeline
Lenz Therapeutics and Corxel release positive phase 3 presbyopia data from China
Statistically significant topline data supports LNZ100’s safety profile just days after the FDA accepts LENZ’s NDA for potential U.S. regulatory approval.
Pipeline
FDA accepts Lenz Therapeutics’ NDA for presbyopia eye drops
PDUFA target action date on LNZ100 (1.75% aceclidine) is set for August 2025
Pipeline
Lenz Therapeutics submits NDA for presbyopia eye drop
FDA has 60 days to review LNZ100 (1.75% aceclidine) as a pupil-selective and long-lasting therapeutic option.
Pipeline
LENZ Therapeutics reports positive phase 3 data for presbyopia eye drops
CLARITY 1 and 2 trials report statistically significant topline data for single-use, once-daily, and preservative-free LNZ100.
Business
Lenz Therapeutics merges with Graphite Bio
Combined company under LENZ is focusing on advancing two presbyopia therapeutic candidates.
Business
LENZ Therapeutics and Graphite Bio are merging to focus on presbyopia
The $225 million agreement will be used to advance the lead programs for 2 investigational eye drops.Pipeline